Biden Administration Recommends Policy Changes to Secure U.S. Pharmaceutical Supply Chain
June 18, 2021
In last week’s BioUtah News and Events, we highlighted the Biden Administration’s formation of a task force to address a range of supply chain issues. This week, we share the findings of the administration’s 100-day assessment of critical supply chains, undertaken pursuant to President Biden’s February 2021 “America’s Supply Chains” executive order addressing supply chain vulnerabilities.
An HHS press release states that “the report reveals the pharmaceutical supply chain as complex, global, and highly influenced by market factors that have led to an increasing reliance on foreign countries to manufacture the medicines, active pharmaceutical ingredients (APIs) and key starting materials (KSMs) that serve the American public.”
The 100-day assessment report identifies steps needed to boost domestic manufacturing of critical products and lessen dependence on foreign countries in initially four key sectors, including active pharmaceutical ingredients.
The executive order also calls for a one-year review of the domestic supply chains of six additional industries: defense, public health and biological preparedness, information and communications technology, energy, transportation, and agriculture and food production.
Recent News
- Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
- Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
- NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
- CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
- Seek Labs Unveils BioSeeker™
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)